

WHAT IS CLAIMED IS:

1. A method of suppressing ongoing acute allograft rejection, which method comprises administering to a host experiencing ongoing acute allograft rejection an interleukin-10 (IL10) inhibitor and an interleukin-2 (IL2) inhibitor in amounts effective to rescue the allograft from ongoing acute rejection.
2. The method of claim 1, wherein said IL10 inhibitor is an IL10 antagonist.
- 10 3. The method of claim 2, wherein said IL10 antagonist is an anti-IL10 antibody.
4. The method of claim 2, wherein said IL10 antagonist is an IL10 receptor antagonist.
- 15 5. The method of claim 4, wherein said IL10 receptor antagonist is an anti-IL10 receptor antibody.
6. The method of claim 1, wherein said IL10 inhibitor is a compound which blocks the upstream or downstream signals of IL10.
- 20 7. The method of claim 1, wherein said IL10 inhibitor and said IL2 inhibitor are administered during acute rejection.
- 25 8. The method of claim 1, wherein said allograft is selected from the group consisting of heart, kidney, liver, lung, pancreas, bladder, small intestine, and skin.
9. The method of claim 1, wherein the inhibitor of IL2 is an inhibitor of IL2 mRNA transcription.
- 30 10. The method of claim 9, wherein said inhibitor of IL2 mRNA transcription is cyclosporin A (CsA).

11. A use of an IL10 inhibitor and an IL2 inhibitor in the manufacture of a medicament for suppressing ongoing acute allograft rejection in accordance with the method of any of claims 1-10.

5 12. A composition comprising an IL10 inhibitor and an IL2 inhibitor as active ingredients for suppressing ongoing acute allograft rejection in accordance with the method of any of claims 1-10.

10 13. A method of suppressing ongoing acute allograft rejection, which method comprises administering to a host experiencing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor, an IL10 inhibitor in an amount effective to rescue the allograft from ongoing acute rejection.

15 14. A use of an IL10 inhibitor in the manufacture of a medicament for suppressing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor.

20 15. A composition comprising an IL10 inhibitor as an active ingredient for suppressing ongoing acute allograft rejection, which is due to insufficient immunosuppression by an IL2 inhibitor.